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Abstract
Background: Randomized clinical trials of oral antiretroviral pre-exposure prophylaxis (PrEP) for HIV prevention have widely
divergent efficacy estimates, ranging from 0% to 75%. These discrepancies are likely due to differences in adherence. To our
knowledge, no studies to date have examined the impact of improving adherence through monitoring and/or intervention,
which may increase PrEP efficacy, or reported on objective behavioral measures of adherence, which can inform PrEP
effectiveness and implementation.
Methods and Findings: Within the Partners PrEP Study (a randomized placebo-controlled trial of oral tenofovir and
emtricitabine/tenofovir among HIV-uninfected members of serodiscordant couples in Kenya and Uganda), we collected
objective measures of PrEP adherence using unannounced home-based pill counts and electronic pill bottle monitoring.
Participants received individual and couples-based adherence counseling at PrEP initiation and throughout the study;
counseling was intensified if unannounced pill count adherence fell to ,80%. Participants were followed monthly to
provide study medication, adherence counseling, and HIV testing. A total of 1,147 HIV-uninfected participants were
enrolled: 53% were male, median age was 34 years, and median partnership duration was 8.5 years. Fourteen HIV infections
occurred among adherence study participants—all of whom were assigned to placebo (PrEP efficacy=100%, 95%
confidence interval 83.7%–100%, p,0.001). Median adherence was 99.1% (interquartile range [IQR] 96.9%–100%) by
unannounced pill counts and 97.2% (90.6%–100%) by electronic monitoring over 807 person-years. Report of no sex or sex
with another person besides the study partner, younger age, and heavy alcohol use were associated with ,80% adherence;
the first 6 months of PrEP use and polygamous marriage were associated with .80% adherence. Study limitations include
potential shortcomings of the adherence measures and use of a convenience sample within the substudy cohort.
Conclusions: The high PrEP adherence achieved in the setting of active adherence monitoring and counseling support was
associated with a high degree of protection from HIV acquisition by the HIV-uninfected partner in heterosexual
serodiscordant couples. Low PrEP adherence was associated with sexual behavior, alcohol use, younger age, and length of
PrEP use.
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Over 2.5 million people are infected with HIV each year
globally [1]. HIV antiretroviral medications, whether given to
an HIV-infected person to reduce infectiousness or as pre-
exposure prophylaxis (PrEP) to an HIV-uninfected person to
prevent acquisition, hold great promise for decreasing the
number of new infections. PrEP has strong biologic plausibility
for HIV prevention [2]; however, randomized clinical trials of
PrEP have generated conflicting results. Three studies have
shown protection against HIV infection with efficacy estimates
ranging from 44%–75% [3–5], while two other studies have
been stopped in whole or in part because of futility to
demonstrate efficacy [6,7].
Adherence to antiretroviral medications is essential for
efficacious treatment of HIV infection [8], and adherence to
antiretroviral PrEP is also likely important for HIV prevention.
Thus, differential adherence across clinical trials of PrEP is the
leading hypothesis to explain the differences in clinical trial
efficacy estimates [9,10]. Supporting this theory, trials demon-
strating efficacy for HIV protection have shown close relation-
ships between detection of antiretroviral medications in blood
samples and HIV protection [3,4]. Notably, two of the trials that
failed to demonstrate PrEP efficacy detected antiretroviral
medication in blood samples from only a minority of partici-
pants [7,11]. Moreover, a recent modeling study indicated 99%
risk reduction of HIV infection when PrEP is taken 7 days a
week [12].
Clinical trials of PrEP have used several measures to estimate
adherence to the study medication, including participant reports of
missed doses, clinic-based pill counts of unused medication, and
blood levels of the antiretroviral medications. Each measure has
important limitations. Participant report often overestimates
adherence owing to social desirability bias and failure to
remember missed doses [13]. Clinic-based pill counts are an
objective measure; however, they are often susceptible to
participant manipulation prior to the clinic visit (i.e., pill dumping)
[14]. Blood levels of antiretroviral medications are similarly subject
to manipulation in that participants may take medications just
before a scheduled study visit when they know that drug levels will
be drawn [15]. Moreover, because drug levels are subject to both
behavioral (i.e., time of dosing) and biological variation (i.e.,
pharmacokinetics), they may poorly correlate with actual adher-
ence behavior; in one study of antiretroviral treatment, blood
levels of drug were only modestly associated with HIV viral
suppression [16]. Objective behavioral adherence measures may
improve understanding of the relationship between adherence
behavior and PrEP protection against HIV. Additionally, other
trials have not systematically involved the provision of further
adherence support for those with poor adherence who would like
to continue taking PrEP in the trial.
Within a randomized, placebo-controlled, clinical trial of daily
oral PrEP (the Partners PrEP Study), we enrolled subjects into a
substudy designed to monitor and improve adherence. Two
objective measures of adherence behavior (unannounced home-
based pill counts [UPC] and the medication event monitoring
system [MEMS]), were utilized to monitor adherence. A two-
stepped approach to adherence counseling was also employed,
which involved initial adherence counseling, followed by more
intensive counseling for those who fell to ,80% adherence from
the UPC monitoring. Here, we estimate the efficacy of PrEP in the
context of both intensive adherence monitoring and counseling, as
well as characterize PrEP adherence behavior and examine factors
associated with low adherence.
Methods
Ethics Statement
The study protocol was approved by the human subjects
committees of Massachusetts General Hospital/Partners Health-
care, the University of Washington, the Centers for Disease
Control and Prevention, the Uganda National Council for Science
and Technology, and the Uganda Virus Research Institute
Science and Ethics Committee.
Partners PrEP Study
The Partners PrEP Study was a phase III, randomized, double-
blind, placebo-controlled, three-arm clinical trial of daily oral
tenofovir (TDF) and emtricitabine/tenofovir (FTC/TDF) PrEP
provided to HIV-uninfected members of 4,758 HIV serodiscor-
dant couples attending nine clinical research sites in Kenya and
Uganda. Enrollment began in July 2008 and concluded in
November 2010. Retention was high at 97% at 1 year and 96%
at 2 years of individual follow-up. The design, procedures, and
outcomes of the Partners PrEP Study clinical trial are described
elsewhere [3]. Briefly, HIV-uninfected partners were randomly
assigned to once-daily TDF, combination FTC/TDF, or matching
placebo and followed monthly for safety assessments and HIV
seroconversion for up to 36 mo. Adherence was measured with
clinic-based pill counts and self-report at the monthly visits. HIV-
infected partners were not eligible for antiretroviral therapy under
national guidelines at the time of enrollment, but were monitored
and actively referred for antiretroviral treatment initiation if they
became eligible during the course of follow-up. All couples
received a package of HIV prevention services, including risk-
reduction counseling, couples counseling, and condoms. In July
2011, the independent Data and Safety Monitoring Board
recommended public report of the results and discontinuation of
the trial placebo arm due to demonstration of 67% efficacy for
HIV protection with TDF and 75% efficacy with FTC/TDF.
Adherence Substudy
In November 2009, we initiated a substudy to objectively
measure and support adherence at three of the Partners PrEP
Study sites (Kabwohe, Kampala, and Tororo: all in Uganda). A
convenience sample was selected from those already enrolled or
simultaneously enrolling in the main clinical trial and who had at
least 6 mo of follow-up remaining in the main clinical trial;
participants included all study arms (which were blinded at the
time) and no other selection criteria were used. In the adherence
substudy, additional adherence assessment was performed using
two validated objective measures. First, UPC were conducted at
the participant’s home unannounced (i.e., participants were not
informed of the date of the visit) on a randomly selected day every
month for the first 6 mo and quarterly thereafter. The random
nature of the visit was intended to reduce the chance that
participants would manipulate pill bottles (i.e., dump pills) prior to
the measurement. Second, MEMS (Aardex) were used to
electronically record the date and time of pill bottle openings;
data were downloaded monthly. Both UPC and MEMS have been
closely correlated with each other and with HIV RNA suppression
when measured in HIV-infected individuals on antiretroviral
therapy in Uganda and San Francisco [17,18], although both
measures are still susceptible to manipulation. Participants found
to have UPC adherence ,80% were enrolled in a manualized,
customizable, multi-session adherence intervention [19]. The
intervention modules were consistent with principles of cognitive
behavioral therapy and problem-solving therapy. Accordingly, the
intervention began with psycho-educational information and
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assistance with specific problem-solving strategies. Because the
study population consisted of individuals in serodiscordant
partnerships, the intervention included a couples-based compo-
nent, such that the initial portion of the session was conducted with
just the participant taking PrEP, and the second part with both
members of the dyad (optional, but encouraged). The intervention
was designed to be approximately 30–45 min long at the initial
session with shorter subsequent sessions, and participants could
have as many sessions as they or the counselors felt would be useful
(average 6.8 per participant taking PrEP with range of 1 to 16).
This article presents data collected through the July 2011
announcement of HIV protection efficacy in the main clinical
trial, at which time enrollment in the substudy concluded.
Statistical Analysis
All statistical analyses were conducted with SAS 9.2 and Stata
12.0. Characteristics of study participants enrolled and not
enrolled in the adherence study were compared with Fisher’s
exact test for categorical covariates, and Wilcoxon rank sum test
for continuous covariates. Efficacy of PrEP while in the adherence
substudy was estimated by 1 minus the incidence rate ratio (IRR).
The 95% exact confidence interval for the IRR was used.
Adherence by UPC and MEMS was estimated by the number
of pills taken during the study quarter divided by the number of
days the participant would be expected to take the pills, excluding
days when a protocol-defined drug hold was in effect (e.g., for
adverse events or pregnancy, which was defined by a positive urine
test performed at each monthly visit in the Partners PrEP Study).
Overall participant adherence was calculated using this same
method, except that the interval in question was the entire study
period for that individual rather than the quarter. When UPC was
performed once a quarter (i.e., after 6 mo of follow-up), the UPC
was used to estimate how many pills had been taken since the last
clinic visit; clinic pill count data were used to estimate adherence
during the time between visits. MEMS data were unadjusted
except to account for pill bottle openings by study staff. Adherence
values .100% may have occurred due to additional doses (e.g.,
multiple pills taken per day) or limitations of the adherence
measurements. For instance, a participant may have manipulated
the pill count (i.e., dumped pills prior to the measurement) or a
participant may have opened a MEMS bottle numerous times
without removing pills (e.g., due to curiosity). UPC and MEMS
adherence were compared by Spearman’s correlation. Low
adherence was defined as ,80% adherence in a quarter,
paralleling the trigger used for the adherence intervention in this
study. The threshold value of 80% was chosen based on biologic
plausibility [20] and is consistent with high adherence as defined in
another PrEP study [21], although the exact level of adherence
needed to protect against HIV acquisition is unknown.
Potential associations with ,80% UPC and MEMS adherence
were evaluated using univariable and multivariable (adjusted)
generalized estimating equation (GEE) models with logistic link
and robust standard errors to account for repeated measures.
Variables assessed on a monthly basis were categorized to reflect
any reported behaviors during the quarter (e.g., no sex indicates
no sex in the entire quarter). Variables were measured concur-
rently with adherence behavior. Enrollment and time-varying
characteristics were assessed for both the HIV-uninfected and
HIV-infected partners. Socio-economic status index was evaluated
via a principal components analysis based on the Filmer-Pritchett
Index and involved the presence of running water, a concrete
floor, electricity, a metal roof, a television, and two or more rooms
in the residence [22]. Heavy alcohol use was defined as a positive
Rapid Alcohol Problems Screen [23]. Depression was assessed by
the Hopkins Checklist, using 1.75 as a cut-off [24]. Belief in PrEP
efficacy was assessed by standardized questionnaire prior to the
release of efficacy data in July 2011. Adjustment in the
multivariable model was for site and variables for which the p-
value on univariable analysis was ,0.10. Where CD4 count at
enrollment and at follow-up were both significantly related at
p,0.10, only the stronger CD4 count variable was carried forward
to the multivariate analysis. The presence of different effects by
gender for sex behaviors and for polygamous relationships were
evaluated by testing interaction terms with gender in the GEE
model; these variables were chosen a priori as likely to have
different effects on adherence by gender.
Findings
Study participants
A total of 1,185 seronegative participants were considered for
enrollment in the adherence substudy; 38 (3.2%) were not enrolled
due to refusal, having less than 6 mo of follow-up remaining in the
clinical trial, or logistical reasons that would interfere with home
visits; 1,147 participants were enrolled in the study, reflecting 66%
of all participants in the three study sites. Table 1 shows the
individual and partnership characteristics for the participants in
the Partners PrEP Study and in the adherence substudy (total and
by arm in the substudy) at enrollment. Characteristics are also
presented for those Partners PrEP Study participants who were
based in the sites of the adherence substudy, but did not
participate in the adherence substudy.
Among participants in the adherence substudy, 53% were male,
the median age was 34 y (interquartile range [IQR] 30–40), and
35% were taking placebo. Nearly all (99%) were married with a
median duration of partnership of 8.5 y (IQR 3.7–15.3) and 29%
reported unprotected sex within the past month. The median CD4
count for the HIV-infected partner was 491 cells/ml (IQR 368–
667). When comparing participants in the adherence substudy to
participants in the overall Partners PrEP Study, notable differences
include fewer males (53% versus 62%), somewhat longer
partnerships (median 8.5 y versus 7.0 y), and a slightly higher
rate of polygamy (25% versus 21%). These differences in male
gender and partnership duration were also seen when comparing
individuals who did and did not participate in the adherence
substudy at the three sites where the substudy took place; however,
rates of polygamous marriage were more similar (25% versus
27%). Additionally, more participants were on placebo (34%
versus 31%) and unprotected sex in the prior month was
somewhat more common (29% versus 25%). Characteristics
across study arms were very similar.
Because most participants enrolled in the adherence substudy
subsequent to their enrollment in the clinical trial, varying periods
of time on PrEP were observed; specifically, 388 (34%) partic-
ipants contributed data during 0–6 mo on PrEP, 593 (52%) during
7–12 mo, 606 (53%) during 13–18 mo, 540 (47%) during 19–
24 mo, and 385 (34%) beyond 24 mo. Retention was high at 94%
and 93% at 12 mo and 18 mo, respectively, for clinic visits, and 83
and 89% for 12 and 18 mo, respectively, for home visits. Average
follow-up was 11.3 study mo (standard deviation [SD] 5.2).
PrEP efficacy
Among participants enrolled in the adherence substudy, 14
acquired HIV during follow-up. All 14 were participants
randomized to placebo (among 404 participants contributing
333 person-years). Participants randomized to the two active PrEP
arms acquired 0 infections (among 750 participants contributing
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prevention in the adherence substudy population was 100%
(95% CI 83.7%–100%, p,0.001).
Summary of adherence
Objective behavioral adherence measures from the adherence
substudy are summarized in Table 2. Median overall participant
adherence was 99.1% (IQR 96.9%–100%) by UPC and 97.2%
(IQR 90.6%–100%) by MEMS. Adherence was similar between
genders, among the study arms, and over time. Single openings
per day were recorded for 96.7% of all days covered in the
study, and 95.0% of the remaining days indicated two openings.
Because those openings may have reflected true dosing behavior
(e.g., one pill early one morning and another pill late that night
for use during the next day), MEMS data were not adjusted for
analysis. As shown in Figure 1, the distribution of adherence
includes values .100%, but adherence was .110% in only
1.5% of quarters measured by UPC and 1.0% of quarters
measured by MEMS. UPC and MEMS were significantly
correlated at 0.5 (p,0.0001). A total of 71 (6.8%) and 282
(25.8%) participants had ,80% adherence for at least one
quarter during the study by UPC and MEMS, respectively.
Greater than 80% adherence was seen at 6 mo, 12 mo, 18 mo,
and 24+ mo of PrEP use in 97.6%, 96.8%, 97.5%, and 98.7% of
participants by UPC and 86.2%, 82.2%, 85.4%, and 87.8% by
MEMS, respectively. Pill sharing was reported by no partici-
pants in the adherence substudy.
Factors associated with low (,80%) adherence
Tables 3 and 4 present the univariable and multivariable
regression analyses for ,80% adherence by UPC and MEMS,
respectively. Incident pregnancy and reports of abuse (verbal,
physical, and economic; assessed monthly) were of interest, but too
rare to assess for potential associations with adherence. Factors
independently associated with ,80% UPC adherence on multi-
variable analysis (referencing the HIV-uninfected partner, unless
otherwise stated) were report of no sexual activity (adjusted odds
ratio [AOR]=4.2; 95% CI 1.9–9.4) and sex with both the study
partner and another partner (AOR=3.0; 95% CI 1.5–5.9) within
the previous month, younger age (AOR=1.4; 95% CI 1.0–2.0;
per decade), and heavy alcohol use (AOR=2.8; 95% CI 1.4–5.5).
Being in a formal polygamous marriage (i.e., not simply having
more than one sexual partnership; AOR=0.4; 95% CI 0.2–0.9)
was associated with a lower likelihood of ,80% UPC adherence.
Similarly, factors independently associated with ,80% MEMS
adherence were report of no sex (AOR=2.3; 95% CI 1.5–3.3) and
sex with both the study partner and another partner (AOR=1.6;
95% CI 1.1–2.4) in the previous month, and younger age
(AOR=1.7; 95% CI 1.3–2.1; per decade). Being in a polygamous
relationship was also associated with a lower likelihood of ,80%
Table 1. Enrollment characteristics of study participants.
Characteristics
Partners PrEP
Participants Adherence Substudy Sites
Total TDF Arm FTC/TDF Arm Placebo Arm
Participant Not
Enrolled
a
n (%) or Median (IQR)
Individual characteristics n=4,747 n=1147 n=359 n=386 n=402 n=597
Male gender 2,962 (62%) 608 (53%) 196 (55%) 203 (53%) 209 (52%) 349 (58%)
Years of education 7 (4–10) 6 (3–7) 6 (3–8) 6 (3–8) 6 (3–8) 6 (3–9)
Age in years 33 (28–40) 34 (30–40) 34 (29–40) 35 (30–40) 34 (30–40) 34 (28–40)
Placebo 1,584 (33%) 402 (35%) n/a n/a n/a 183 (31%)
Entry into the adherence study
Concurrent with trial enrollment n/a 290 (25%) 97 (27%) 100 (26%) 93 (23%) n/a
Months 1–6 n/a 182 (16%) 62 (17%) 56 (15%) 64 (16%) n/a
Months 7–12 n/a 202 (18%) 61 (17%) 68 (18%) 73 (18%) n/a
After month 12 n/a 473 (41%) 139 (39%) 162 (42%) 172 (43%) n/a
Partnership characteristics
Married 4,635 (98%) 1,135 (99%) 353 (98%) 383 (99%) 399 (99%) 581 (97%)
Living together 4,650 (98%) 1,129 (98%) 353 (98%) 382 (99%) 394 (98%) 585 (98%)
Number of years living together 7.0 (3.0–14.0) 8.5 (3.7–15.3) 8.2 (3.6–15.0) 8.0 (3.7–15.3) 9.0 (3.8–15.9) 7.1 (3.0–14.2)
Number of children in the partnership 2 (1–4) 2 (1–4) 2 (1–4) 2 (1–4) 2 (1–4) 2 (1–4)
Polygamous marriage 974 (21%) 282 (25%) 82 (23%) 104 (27%) 96 (24%) 158 (27%)
Age difference between partners 1 (24t o6 ) 0( 25t o5 ) 1( 26t o5 ) 0( 26t o5 ) 0( 25t o5 ) 0( 26t o6 )
Unprotected sex in prior month 1267 (28%) 321 (29%) 107 (30%) 111 (30%) 103 (26%) 142 (25%)
HIV-infected partner CD4 count (cells/mm
3) 495 (375–662) 491 (368–667) 464 (348–626) 503 (380–682) 504 (372–687) 477 (355–645)
HIV-infected partner viral load (log copies/ml) 3.9 (3.2–4.5) 4.0 (3.3–4.6) 4.1 (3.4–4.6) 3.9 (3.2–4.5) 4.0 (3.4–4.6) 4.0 (3.3–4.6)
Complete data were available on all variables (n=1,147) except for questions regarding unprotected sex in the prior month (missing in 3%), polygamy (,1%), and viral
load (1%).
aFrom the three sites from which the adherence substudy recruited.
n/a, not applicable.
doi:10.1371/journal.pmed.1001511.t001
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doi:10.1371/journal.pmed.1001511.g001
Table 2. Summary of adherence by measure.
Description Unannounced Pill Count MEMS
Median (IQR) Mean (SD) n Median (IQR) Mean (SD) n
Overall 99.1% (96.9–100%) 97.6% (7.1) 1,041
a 97.2% (90.6–100%) 91.1% (17.2) 1,093
a
By site
Kabwohe 99.1% (97.5–100%) 97.2% (7.7) 349 98.2% (92.9–100%) 95.1% (9.3) 357
Kampala 98.8% (96.1–100%) 97.0% (8.1) 351 92.9% (77.7–97.8%) 82.6% (23.2) 369
Tororo 99.4% (97.5–100%) 98.5% (5.1) 341 98.9% (94.8–100%) 95.9% (12.2) 367
By gender
Female 99.3% (97.4–100%) 98.0% (6.6) 491 98.2% (92.9–100%) 93.7% (14) 509
Male 98.8% (96.3–100%) 97.3% (7.6) 550 96.2% (88.3–99.5%) 88.9% (19.3) 584
By study arm
TDF 99.1% (96.5–100%) 97.0% (8.6) 352 96.9% (90.5–100%) 90.4% (18.4) 339
FTC/TDF 99.2% (97.2–100%) 97.8% (6.5) 367 97.3%(90.8–100%) 91.6%(16.8) 367
Placebo 99.1% (96.7–100%) 97.9% (6.4) 322 97.3% (90.5–100%) 91.4% (16.5) 387
By quarter since enrollment into the
adherence substudy
Q1 (M1–3) 100.0% (97.1–100%) 98.5% (11.8) 922 98.8% (92.9–100%) 93.8 (15.3) 1,093
Q2 (M4–6) 100.0% (97.1–100%) 98.2% (7.7) 933 97.6% (91.7–100%) 91.8 (18.6) 946
Q3 (M7–9) 100.0% (96.5–100%) 97.8% (8.3) 686 97.6% (91.5–100%) 89.5 (23.1) 799
Q4 (M10–12) 98.9% (96.2–100%) 97.2% (8.6) 524 97.6% (89.3–100%) 88.2 (24.7) 649
Q5 (M13–15) 99.2% (96.9–100%) 97.6% (8.0) 399 96.5% (89.2–100%) 87.3 (25.1) 487
Q6 (M16–18) 98.8% (96.1–100%) 96.9% (8.5) 238 96.3% (85.5–100%) 87 (26.2) 287
Q7 (M19–21) 98.8% (96.9–100%) 98.0% (4.5) 64 98.2% (91.0–100%) 90.3 (19.1) 96
aUnannounced pill counts and MEMS were planned for all 1,147 participants. For 46 participants, however, MEMS data were not expected because of enrollment shortly
prior to the data analysis cut-off date and the lack of a subsequent clinic visit for uploading MEMS data. MEMS data were not available for eight (0.7%) of 1,101
participants with expected MEMS data owing to factors such as missing visits, device malfunction, or device loss. Similarly, for 70 participants, enrollment was too close
to the data analysis cut-off date to expect a UPC following initiation of pill counting. Attempts at UPC were not successful for 36 (3.3%) of the remaining 1,077
participants.
Q, quarter; M, month.
doi:10.1371/journal.pmed.1001511.t002
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Factors
Prevalence
or Mean (SD)
Quarters
with ,80%
Adherence
a
Univariable
OR (95% CI) p-Value*
Multivariable
AOR (95% CI) p-Value*
HIV-uninfected partner, enrollment characteristics
Younger age (per decade) 35.7 (8.2) 32.7 (7.0) 1.7 (1.2–2.3) 0.001 1.4 (1.0–2.0) 0.04
Male 53% 53 (2.7%) 1.6 (1.0–2.7) 0.05 1.0 (0.5–1.7) 0.87
Randomized to active study drug (versus placebo) 65% 53 (2.2%) 1.1 (0.6–1.8) 0.83 — —
Years of education$6 52% 47 (2.4%) 1.2 (0.8–2.0) 0.39 — —
HIV-infected partner, enrollment characteristics
CD4 count: 0.28
,350 cells/ml 25% 14 (1.5%) 0.6 (0.3–1.2) — —
350–500 cells/ml 29% 25 (2.3%) 0.9 (0.5–1.6)
.500 cells/ml 46% 43 (2.5%) reference
HIV-uninfected partner, time varying characteristics
(in the past quarter)
Socio-economic status index 20.01 (1.00) 0.31 (1.09) 1.2 (1.0–1.5) 0.05 1.2 (0.9–1.6) 0.21
Primary income from farming 60% 34 (1.5%) 0.5 (0.3–0.8) ,0.01 0.7 (0.3–1.3) 0.23
Heavy alcohol use 6% 10 (4.2%) 2.2 (1.1–4.5) 0.03 2.8 (1.4–5.5) 0.004
Depression 5% 2 (1.0%) 0.5 (0.1–1.9) 0.13 — —
Travel time from home to clinic: 0.52
,30 min 2% 1 (1.5%) 0.7 (0.4–1.3)
30–59 min 10% 11 (2.9%) 1.2 (0.5–2.9) — —
1–2 h 35% 22 (1.7%) 0.6 (0.1–4.4)
.2 h 53% 46 (2.3%) reference
Number of side effects 0.4 (0.6) 0.4 (0.6) 0.9 (0.6–1.4) 0.68 — —
Sexual behavior in the previous month 0.0004 0.01
No sex 5% 10 (5.7%) 4.5 (2.1–9.4) 4.2 (1.9–9.4)
Primary partner only, 100% condom use 55% 27 (1.3%) reference reference
Primary partner only, ,100% condom use 22% 20 (2.5%) 1.9 (1.0–3.4) 1.7 (0.9–3.1)
Other partner only 2% 2 (2.2%) 1.7 (0.4–7.0) 1.5 (0.3–7.0)
Other partner+primary partner 15% 21 (3.7%) 2.3 (1.2–4.3) 3.0 (1.5–5.9)
Disclosure of partner’s HIV status to anyone 68% 57 (2.3%) 1.2 (0.6–2.1) 0.64 — —
Belief in PrEP: HIV medicines prevent HIV 25% 18 (1.9%) 0.9 (0.5–1.6) 0.67
PrEP use before sex prevents HIV 15% 8 (1.5%) 0.7 (0.3–1.5) 0.25 — —
The study pill makes sex safe 19% 12 (1.7%) 0.8 (0.4–1.5) 0.43
Months on PrEP 0.08 0.45
1–6 mo 17% 15 (2.4%) 1.9 (0.8–4.5) 1.3 (0.5–3.3)
7–12 mo 22% 26 (3.2%) 2.5 (1.1–5.5) 1.8 (0.8–4.0)
13–18 mo 22% 20 (2.5%) 1.9 (0.9–4.3) 1.4 (0.6–3.3)
19–24 mo 21% 10 (1.3%) 1.0 (0.4–2.4) 0.9 (0.4–2.2)
25+ mo
b 19% 9 (1.3%) reference reference
HIV-infected partner, time-varying characteristics
(in the past quarter)
CD4 count: 0.30
,200 cells/ml 5% 4 (2.1%) 0.9 (0.3–3.1)
200–349 cells/ml 24% 14 (1.6%) 0.7 (0.4–1.2) — —
.350 cells/ml 71% 64 (2.4%) reference
On ART 16% 7 (1.2%) 0.5 (0.2–1.3) 0.15 — —
Partnership, enrollment characteristics
Not living together 2% 2 (2.9%) 1.3 (0.3–5.7) 0.70 — —
No children with partner 20% 20 (2.6%) 0.6 (0.2–1.8) 0.34 — —
Polygamous marriage 23% 10 (1.1%) 0.4 (0.2–0.9) 0.02 0.4 (0.2–0.9) 0.03
Less than 80% adherence was seen among 71 participants in 2.3% of study quarters. UPC data available were available for 3,766 of 4,361 (86.4%) of study quarters.
an (row %) or mean (SD).
bUPC data available were available for 3,766 of 4,361 (86.4%) of study quarters.
*Bold indicates p,0.05.
doi:10.1371/journal.pmed.1001511.t003
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Factors
Prevalence or
Mean (SD)
Quarters
with ,80%
Adherence
a
Univariable
OR (95% CI) p-Value*
Multivariable
AOR (95% CI) p-Value*
HIV-uninfected partner, enrollment characteristics
Younger age (per decade) 35.7 (8.2) 32.1 (7.3%) 2.0 (1.6–2.5) ,0.001 1.7 (1.3–2.1) 0.01
Male 53% 423 (18.1%) 2.0 (1.5–2.7) ,0.001 1.3 (0.9–1.9) 0.16
Randomized to active study drug (versus placebo) 65% 417 (14.8%) 1.1 (0.8–1.5) 0.50 — —
Years of education $6 52% 416 (19.1%) 2.0 (1.5–2.7) ,0.001 1.0 (0.7–1.4) 0.96
HIV-infected partner, enrollment characteristics
CD4 count: 0.03
,350 cells/ml 25% 113 (10.8%) 0.7 (0.4–0.9) — —
350–500 cells/ml 29% 183 (14.2%) 0.8 (0.6–1.2)
.500 cells/ml 46% 329 (16.3%) reference
HIV-uninfected partner, time varying characteristics (in
the past quarter)
Socio-economic status index 20.01 (1.00) 0.57 (1.15) 1.6 (1.4–1.8) ,0.001 1.1 (0.9–1.3) 0.47
Primary income from farming 60% 223 (8.5%) 0.3 (0.2–0.4) ,0.001 0.8 (0.5–1.2) 0.22
Heavy alcohol use 6% 40 (14.5%) 1.0 (0.6–1.7) 0.91 — —
Depression 5% 36 (15.7%) 1.1 (0.6–2.1) 0.67 — —
Travel time from home to clinic: 0.01 0.25
,30 min 2% 8 (10.7%) 0.9 (0.3–2.8) 0.6 (0.2–1.9)
30–59 min 10% 96 (22.4%) 2.2 (1.4–3.3) 1.3 (0.8–2.1)
1–2 h 35% 239 (16.0%) 1.4 (1.1–1.9) 0.9 (0.6–1.2)
.2 h 53% 277 (11.8%) reference reference
Number of side effects 0.4 (0.6) 0.4 (0.6) 0.9 (0.7–1.1) 0.20 — —
Sexual behavior in the past month ,0.001 ,0.001
No sex 5% 64 (25.6%) 2.7 (1.9–3.8) 2.3 (1.5.3.3)
Primary partner only, 100% condom use 55% 267 (11.9%) reference reference
Primary partner only, ,100% condom use 22% 123 (13.0%) 1.2 (0.8–1.6) 1.1 (0.8–1.6)
Other partner only 2% 45 (39.1%) 4.8 (2.9–7.9) 2.3 (1.3–3.8)
Other partner+primary partner 15% 119 (17.7%) 1.7 (1.2–2.4) 1.6 (1.1–2.4)
Disclosure of partner’s HIV status to anyone 68% 346 (11.6%) 0.5 (0.4–0.7) ,0.001 1.0 (0.8–1.4) 0.79
Belief in PrEP: HIV medicines prevent HIV 25% 121 (10.7%) 0.7 (0.5–0.9) 0.01 1.1 (0.7–1.6) 0.76
PrEP use before sex prevents HIV 15% 109 (13.5%) 0.9 (0.6–1.4) 0.73 — —
The study pill makes sex safe 19% 70 (8.2%) 0.5 (0.4–0.6) ,0.001 0.7 (0.5–1.1) 0.13
Months on PrEP 0.01 ,0.001
1–6 mo 17% 94 (13.8%) 1.2 (0.8–1.8) 0.5 (0.3–0.8)
7–12 mo 22% 172 (17.8%) 1.6 (1.2–2.3) 0.9 (0.6–1.4)
13–18 mo 22% 141 (14.6%) 1.3 (0.9–1.8) 0.8 (0.6–1.2)
19–24 mo 21% 114 (12.8%) 1.1 (0.8–1.5) 1.0 (0.7–1.4)
25+ mo 19% 99 (11.7%) reference reference
HIV-infected partner, time-varying characteristics (in the
past quarter)
CD4 count: 0.09 0.82
,200 cells/ml 5% 24 (16.1%) 1.1 (0.6–1.9) 1.1 (0.6–1.9)
200–350 cells/ml 24% 120 (11.5%) 0.7 (0.5–1.0) 1.1 (0.8–1.6)
.350 cells/ml 71% 481 (15.2%) reference reference
On ART 16% 68 (9.9%) 0.6 (0.4–0.9) 0.03 0.8 (0.5–1.2) 0.21
Partnership, enrollment characteristics
Not living together 2% 8 (9.8%) 0.6 (0.2–2.0) 0.43 — —
No children with partner 20% 207 (23.2%) 2.3 (1.4–3.9) 0.001 1.0 (0.6–1.7) 0.92
Polygamous marriage 23% 85 (8.4%) 0.6 (0.4–0.8) ,0.001 0.6 (0.4–1.0) 0.03
Less than 80% adherence was seen among 282 participants in 14.4% of study quarters. MEMS data were available for 4,357 of 4,463 (97.2%) study quarters.
an (row %) or mean (SD).
*Bold indicates p,0.05.
doi:10.1371/journal.pmed.1001511.t004
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associations with ,80% adherence seen only in the MEMS model
were sex only with a partner other than the study partner
(AOR=2.3; 95% CI 1.3–3.8), and shorter time taking PrEP
(AOR=0.5; 95% CI 0.3–0.8) for 1–6 mo compared to more than
24 mo on PrEP. Heavy alcohol use in the HIV-uninfected partner
was not a significant factor in the MEMS model. Testing for
interactions between gender and sexual behavior suggested that
women may have stronger associations with low adherence and
having an outside partner compared with men (AOR for having
an outside partner=3.5 for women versus 0.8 for men by UPC,
and AOR=6.4 for women versus 1.6 for men by MEMS), but
differences in associations by gender were not statistically
significant (p=0.15 and p=0.25, respectively). No difference in
the effect of polygamy was found by gender in either MEMS or
UPC.
Adherence intervention
At the time of the analysis cut-off date (July 2011), a total of 124
participants (10.8%) were observed to have ,80% UPC
adherence. Of these, 13 triggered just prior to the cut-off date,
and 103 (92.8% of the 111 remaining) received at least one
intervention session. The intervention was well received with only
one participant declining to participate. A UPC following the
intervention was available for 66 participants as of the cut-off date.
UPC adherence improved to $80% in 61 participants (92%), and
54 (82%) remained at $80% for the remainder of UPCs
performed.
Discussion
In this substudy of adherence nested within a randomized
clinical trial of PrEP among African HIV serodiscordant couples,
where participants received a combination of both adherence
monitoring and intensive counseling when adherence dropped
below 80%, adherence to PrEP was high by two objective,
validated measures and efficacy of PrEP was 100% (95% CI
83.7%–100%). Because high adherence is a prerequisite for
measured efficacy to approximate biologic efficacy [25], these
results provide confidence in the high efficacy estimate for
protection against HIV found in the larger Partners PrEP Study.
The lack of seroconversions among the adherence study partic-
ipants randomized to PrEP provides further support that PrEP is
highly efficacious against HIV acquisition among highly adherent
PrEP users.
Despite the overall high levels of adherence, adherence ,80%
was observed at some point during a quarterly follow-up interval
in as many as 25.8% of participants over an average of 11.3 mo of
follow-up. Sexual behavior was closely associated with PrEP
adherence. Those participants who reported not having sex were
less likely to adhere to PrEP during that study quarter than those
reporting sex, presumably because they did not perceive them-
selves to be at risk during periods of no sexual activity. Similarly,
participants who reported having sex with another partner (with or
without having sex with the primary partner) may perceive
themselves to be at lower risk, especially if their outside partner is
known to be HIV-uninfected. Additionally, partners within a
formal polygamous marriage were more likely to adhere,
suggesting a desire to reduce the risk of HIV acquisition within
multiple stable and committed partnerships.
Younger age and heavy alcohol use in the HIV-uninfected
partner were associated with a greater likelihood of low PrEP
adherence; these factors are well established as being associated
with lower adherence to antiretroviral treatment in HIV-infected
people [26,27]. The finding of higher adherence in the first 6 mo
of use may reflect initial enthusiasm for a novel prevention method
that may be challenging to sustain over time. Waning adherence
patterns have been seen with daily oral contraceptive pills [28] and
strategies to maintain good adherence over time may be needed.
Adherence counseling, both in the routine sessions and in the
adherence intervention, may have played a role in the high
adherence seen in this study. Adherence for most participants did
increase after the intervention, although the study was not
designed to assess the efficacy of the intervention. Implementation
challenges, however, may influence the extent of counseling to be
provided as PrEP becomes available in demonstration projects and
ultimately clinical care. Further research should focus on
identifying key adherence counseling messages, standardized
approaches for providing appropriate counseling within the ‘‘real
world’’ context, and the cost-effectiveness of adherence interven-
tions. Identifying appropriate counseling approaches will be
critical to ensure the behavioral success of this biological agent
for HIV prevention.
Adherence is difficult to compare among the PrEP clinical trials
that lack comparable measures of adherence behavior. That said,
our data and previously reported data suggest that the degree of
HIV protection is highly correlated with adherence. The highest
levels of PrEP efficacy have been reported for the HIV
serodiscordant couples in the Partners PrEP Study with 75%
protection from FTC/TDF and 67% from TDF [3]. In the TDF-2
study, FTC/TDF conferred 62% protection in young, heterosex-
ual men and women from Botswana who were recruited regardless
of their partner’s serostatus [5], and the iPrEX study found 44%
protection against HIV infection from FTC/TDF among men
who have sex with men [4]. The degree of protection and
corresponding adherence may be the highest in the Partners PrEP
Study because the HIV-uninfected partner taking PrEP received a
higher level of adherence support from his or her HIV-infected
partner and both partners recognized the risk of HIV transmission
[29]. Given that up to 20% of couples in sub-Saharan Africa are
serodiscordant [30], this population may be an ideal target for
initial PrEP implementation strategies. Counseling of the couple,
or another identified support partner for individuals taking PrEP
outside of a partnership, may be a key factor for the success of
PrEP beyond clinical trials. It is important to note, however, that
fewer than 40% of individuals living with HIV know their
serostatus [31]. Further efforts will therefore be needed to scale up
counseling and testing services to identify serodiscordant couples.
The strengths of this study include the use of two objective
behavioral adherence measures; a large sample size; a robust set of
socio-demographic, biological, and behavioral factors potentially
associated with adherence; and the availability of HIV serocon-
version data within a clinical trial. This study also has important
limitations. First, no adherence measure is perfect. Although UPC
and MEMS are significantly correlated and both indicate high
adherence, UPC is consistently somewhat higher than MEMS.
This relationship suggests systematic biases, which have been
similarly reported in the literature [32]. We believe this difference
primarily reflects the removal of multiple doses from the MEMS
pill bottle during a single opening, as may occur when an
individual travels without their pill bottle (often due to inconve-
nience and/or stigma) [33]. Pills lost in between pill counts may
also contribute to misclassification. Pill sharing could also
contribute to misclassification; however, there was no self-reported
pill sharing in this substudy. While social desirability may cause
such self-report to be an underestimate, the high efficacy reported
here and in the clinical trial would be hard to achieve with
widespread pill sharing (see Baeten et al., supplementary materials)
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measurements. Second, due to the small numbers of participants
with low adherence as measured by UPC, the power to identify
factors associated with that measure of adherence was limited.
Factors such as abuse may also be underreported and therefore
difficult to identify. Third, this substudy was conducted within a
blinded randomized controlled trial and recruitment was per-
formed without regard to study arm. Although there were some
differences in the baseline participant characteristics between the
adherence substudy and the clinical trial, these differences were
relatively minor, especially when data are restricted to those sites
at which the substudy took place, and no meaningful differences
were seen across the study arms. It is, however, possible that these
differences influenced the efficacy estimate. Finally, the 80%
threshold may or may not reflect the optimal level of adherence for
protection against HIV acquisition. This study cannot assess
whether non-adherence correlated with HIV infection because no
individuals in the treatment groups became infected.
Identifying participants with ,80% adherence for intensifica-
tion of adherence counseling may have played an important role
in achieving high efficacy in this adherence study. However, timely
identification of adherence problems in general is a challenge even
within clinical trials. Incomplete adherence is typically detected
weeks to months after it occurs, which in the case of PrEP may
result in seroconversion. Real-time adherence monitoring has
recently been shown to be feasible within developing settings [34].
If affordable, such monitoring could be used to identify people
taking PrEP for targeted, enhanced adherence support.
In summary, we found both high levels of adherence and a high
degree of protection against HIV infection in a substudy within a
clinical trial of oral PrEP using two objective and validated
measures of adherence. These data provide further support that
PrEP is highly efficacious at preventing HIV acquisition when it is
taken. Our data also suggest that future development of risk
reduction strategies and adherence interventions in the imple-
mentation setting should address sexual behavior, risk perception,
and heavy alcohol use, especially for young PrEP takers and
prolonged PrEP use. Proper support and assessment of adherence
will be critical for determining efficacy of PrEP outside of clinical
trials. This data will be important for guiding ethical decisions
about resource allocation for both prevention and treatment of
HIV.
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Background. Every year, about 2.5 million people (mostly
living in sub-Saharan Africa) become infected with HIV, the
virus that causes AIDS. HIV, which is usually transmitted
through unprotected sex with an HIV-infected partner,
destroys immune system cells, leaving infected individuals
susceptible to other infections. There is no cure for AIDS,
although antiretroviral drugs can hold HIV in check, and there
is no vaccine against HIV infection. Individuals can reduce
their risk of HIV infection by abstaining from sex, by having
onlyoneor a few lowrisk sexual partners, and by alwaysusing
a condom. In addition, antiretroviral drugs can potentially be
used in two ways to reduce HIV transmission. First, these
drugs could be given to HIV-positive individuals to reduce
their infectiousness. Second, antiretroviral drugs could be
given to HIV-uninfected people to reduce acquisition of the
virus. This approach—pre-exposure prophylaxis (PrEP)—has
provided varying levels of protection against HIV infection in
randomized controlled trials (RCT; studies that monitor the
outcomes of groups of patients randomly assigned to receive
different test drugs or a placebo/dummy drug).
Why Was This Study Done? One hypothesis for the
varying efficacy of PrEP in RCTs is differential adherence—
differences in whether trial participants took the antiretro-
viral drugs correctly. Antiretroviral drugs only control HIV
infections effectively when they are taken regularly and
adherence to antiretroviral PrEP is probably also important
for HIV prevention. Here, the researchers investigate adher-
ence to antiretroviral prophylaxis in a substudy within the
Partners PrEP Study, a placebo-controlled RCT of oral
antiretroviral drugs among nearly 5,000 HIV-uninfected
members of serodiscordant couples in East Africa. In
serodiscordant couples, only one partner is HIV-positive;
20% of couples in Africa who know their HIV status are
serodiscordant. In the Partner PrEP Study, the efficacy of HIV
protection with oral antiretroviral drugs was 67%–75%.
What Did the Researchers Do and Find? The researchers
selected a ‘‘convenience’’ sample—a sample is taken non-
randomly from a population that is close at hand—of 1,147
HIV-uninfected partners enrolled in Uganda. They used
unannounced home-based pill counts (an approach that
reduced the chance of participants dumping unused pills to
appear more adherent than they actually were) and
electronic pill bottle monitoring (a microchip in the
medication bottle cap recorded whenever the bottle was
opened) to measure PrEP adherence in this cohort. All the
participants received adherence counseling at PrEP initiation
and throughout the study; counseling was intensified if
unannounced pill count adherence fell below 80%. Fourteen
participants, all of whom had been assigned to placebo,
became HIV-positive during the adherence substudy. The
average adherence to PrEP was 99.1% and 97.2% as
measured by unannounced pill counts and by electronic
monitoring, respectively. About 7% and 26% of participants
had less than 80% adherence as measured by unannounced
pill count and electronic monitoring, respectively, during at
least one 3-month period of the substudy. Greater than 80%
adherence was associated with the first 6 months of PrEP use
and polygamous marriage. Adherence less than 80% was
associated with report of no sex or sex with another person
besides the study partner, younger age, and heavy alcohol
use. Finally, the adherence intervention (intensified counsel-
ing) was well received and in the first unannounced pill
count after the intervention, adherence increased to above
80% in 92% of participants.
What Do These Findings Mean? These findings indicate
that the high level of PrEP adherence achieved in the setting
of active adherence monitoring and counseling support was
associated with a high level of protection from HIV
acquisition by the HIV-uninfected partner in heterosexual
serodiscordant couples. The findings also suggest that low
PrEP adherence is associated with sexual behavior, alcohol
use, younger age, and length of PrEP use. Several aspects of
the study design may limit the accuracy of these findings.
For example, although the adherence measures used here
are probably more accurate than participant reports of
missed doses and clinic-based pill counts (adherence
measures that are often used in RCTs), they are not perfect.
Nevertheless, these findings provide further support for the
ability of PrEP to prevent HIV acquisition when taken
regularly; they suggest that adherence interventions in the
implementation setting should address sexual behavior, risk
perception, and heavy alcohol use; and they provide data to
guide ethical decisions about resource allocation for
prevention and treatment of HIV infection.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001511.
N The 2012 UNAIDS World AIDS Day Report provides up-to-date
information about the AIDS epidemic and efforts to halt it
N Information is available from the US National Institute of
Allergy and infectious diseases on HIV infection and AIDS
N NAM/aidsmap provides basic information about HIV/AIDS,
summaries of recent research findings on HIV care and
treatment, and information on HIV transmission and
prevention and on PrEP
N Information is available from Avert, an international AIDS
charity, on many aspects of HIV/AIDS, including informa-
tion on HIV and AIDS in Uganda, on HIV prevention, and
on PrEP (in English and Spanish)
N PrEP Watch provides detailed information about PrEP and
links to other resources; it includes personal stories from
people who have chosen to use PrEP
N More information about the Partners PrEP Study is
available
N Personal stories about living with HIV/AIDS are available
through Avert, through Nam/aidsmap, and through the
charity website Healthtalkonline
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